Introduction: The objective of this review was
INTRODUCTION
Psoriasis is a chronic inflammatory disorder seen in approximately 2-3% of the world's population, affecting the skin and often joints.
The most common form is plaque psoriasis, which appears as sharply demarcated, erythematous areas covered with silvery-white scale [1, 2] . The formation of psoriatic plaques involves the interplay of T cells, cytokines, and keratinocytes. The presence of activated T cells within psoriatic plaques and the response to T cell-directed therapy suggest an immunologic nature of the disease [3, 4] . Various cytokines, such as tumor necrosis factor alpha (TNFa), are also present in psoriatic lesions, and may be a target for drug therapy [5] . Both cytokines and activated T cells promote the dysregulated growth of keratinocytes, leading to patches of erythematous, scaly skin.
Although there is no cure, treatment is directed at decreasing the signs and symptoms of psoriasis and modifying the natural progression of the disease. Methotrexate and cyclosporine are systemic agents that have proven efficacy but are limited by various toxicities including liver and kidney complications [1] . Numerous other systemic biologic agents are available and are categorized into three classes: anti-T cell agents (efalizumab, which was removed from the United States market in 2009, and alefacept), anti-TNF agents (infliximab, adalimumab, and etanercept), and antiinterleukin (IL)-12/23 agents (ustekinumab and an investigational agent briakinumab) [6] .
Prior meta-analyses have demonstrated the benefits of these agents on various outcomes in moderate-to-severe plaque psoriasis [7, 8] . This includes studies of the Psoriasis Area and Severity Index (PASI), a traditionally reported endpoint in this area [8] . However, none have comprehensively evaluated the impact of biologics on the physician's global assessment (PGA) or assessments of health-related quality of life (HRQoL). Thus, the authors conducted a systematic review with meta-analysis and Bayesian mixed treatment comparisons (MTC) evaluating the impact of biologics on health outcomes, including the PGA and patientreported HRQoL in patients with moderate-tosevere plaque psoriasis.
METHODS

Search Strategy
Two independent investigators conducted systematic literature searches of MEDLINE 
Study Selection
Studies were included in the evaluation if they were (1) randomized, controlled trials (RCTs) of biologic agents to treat psoriasis versus placebo or each other; (2) conducted in adult patients with moderate-to-severe plaque psoriasis, usually defined as having an inadequate response to topical treatments alone and either having received prior systemic therapy or are candidates for such therapy; and (3) studies that reported efficacy data on clinical or humanistic outcomes. A Preferred Reporting
Items for Systematic Reviews and MetaAnalyses (PRISMA) diagram was constructed for the literature search and selection process to describe the number of citations identified, studies excluded, and studies ultimately included ( Fig. 1 ) [10] .
Validity Assessment
All studies were reviewed and evaluated by two reviewers with disagreement resolved by discussion. The validated Jadad scale was used to assess the methodological quality of included trials [11] . This rating scale assesses inherent controllers of bias by using the following quality assessment criteria: use of and methods for generating randomization; use of and methods for double-blinding; and description of patient withdrawals and dropouts. One point was given for each satisfied criterion. An aggregate score between 0 and 5 was calculated for each included trial (0 = weakest, 5 = strongest), with trials scoring \3 deemed to have lower methodological quality.
Data Abstraction
Through use of a standardized data abstraction tool, two reviewers independently collected data, with disagreement resolved through discussion or triage to a third reviewer. The following information was obtained from each trial:
author identification, year of publication, study design and above-mentioned methodological quality criteria, source of study funding, study population, patient demographics, and co-morbidities.
Study Endpoints
The first endpoint is the PGA, which can be reported as either a static or dynamic scale [12] .
There is no standard PGA, and different versions include six-or seven-point scales, which measure the severity of psoriasis. Terms such as ''clear'' or ''excellent'' (scores of 0 or 1) are used to define the clearing of psoriatic plaques from the skin, with higher scores denoting more severe disease. To measure HRQoL, two scales are used. The first is the (acute or chronic version) 36-item Medical Outcomes Study Short-Form General Health Survey (SF-36). It measures eight domains of HRQoL (physical function, social function, pain, physical and emotional role limitation, vitality, personal perceptions of health, and emotional well-being). Normal scores have a mean of 50, with higher scores being more favorable. The second is the Dermatology Life Quality Index (DLQI), a 10-item questionnaire that assesses the impact of chronic skin conditions on HRQoL, and is frequently used in clinical trials of psoriasis [13] . Scores range from 0 to 30, with 0 representing no disease impact on HRQoL.
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Statistical Analysis
Traditional meta-analysis was initially performed. For the primary analyses, only the US Food and Drug Administration (FDA)-approved doses for each agent were included (for briakinumab, the investigational doses were included). In an attempt to avoid doublecounting individual agents in the analyses, when studies investigated more than one FDAapproved dose, only the highest dose was included in an analysis. This rule was not applied to either ustekinumab or briakinumab, which were not FDA-approved at the time this protocol was developed. Sensitivity analyses were also performed whereby data from all studies were included, regardless of dose. For dichotomous endpoints, weighted averages were reported as odds ratios (ORs) with associated 95% CIs using a DerSimonian and
Laird random-effects model [14] . For traditional meta-analysis for continuous outcomes, Fig. 1 Flow diagram of study selection. PGA physician's global assessment weighted averages were reported using a difference between means, with associated 95% CIs using a DerSimonian and Laird random-effects model [14] .
Statistical heterogeneity was addressed using the I 2 statistic, which assesses the degree of inconsistency across studies and ranges from 0%
to 100% with the higher percentage representing a higher likelihood of the existence of heterogeneity [15] . Visual inspection of funnel plots and Egger's weighted regression statistics were used to assess for the presence of publication bias [16, 17] . In addition to traditional meta-analysis, a MTC meta-analysis was conducted using previously validated WinBUGS code [18] [19] [20] [21] [22] . MTC methods were used to compare the different biologic agents to treat plaque psoriasis. These methods are a generalization of meta-analysis methods because they allow comparisons of agents not addressed within any of the individual trials. A random-effects model was fitted, taking into account the correlation structure induced by multi-arm trials. All MTC analyses were conducted using a Bayesian Markov chain Monte Carlo method and fitted in the freely availably Bayesian Software, WinBUGS.
RESULTS
Literature Search
A total of 1,287 citations were identified through the MEDLINE, Cochrane Central, and manual reference searches (Fig. 1 ). Of these, 31 studies were identified describing the following comparisons (Table 1) : alefacept versus placebo (n = 5) [23] [24] [25] [26] [27] ; efalizumab versus placebo (n = 7) [28] [29] [30] [31] [32] [33] [34] ; infliximab versus placebo (n = 6) [35] [36] [37] [38] [39] [40] ; adalimumab versus placebo (n = 5) [41] [42] [43] [44] [45] ; etanercept versus placebo (n = 4) [46] [47] [48] [49] ; ustekinumab versus placebo (n = 3) [50, 51] ; briakinumab versus placebo (n = 1) [53] . A total of 20 studies were included in the statistical analyses and evaluated FDA-approved doses: alefacept (n = 2) [26, 27] , efalizumab (n = 4) [31] [32] [33] [34] , infliximab (n = 3) [36] [37] [38] , adalimumab (n = 4) [41, 42, 44, 45] , etanercept (n = 3) [46] [47] [48] , ustekinumab (n = 3) [50] [51] [52] , briakinumab (n = 1) [53] .
PGA Static Response Rate
Sixteen RCTs evaluating seven drugs from three classes reported data on the PGA response rate using a static scale (Table 2) Six RCTs evaluated the anti-T cell agents with a single alefacept study [27] and three efalizumab studies [31, 33, 34] reporting results using FDA-approved doses. Seven RCTs evaluated the anti-TNF agents with two infliximab studies [36, 38] , two adalimumab studies [42, 45] , and two etanercept studies [46, 48] evaluating FDA-approved doses. Three RCTs evaluating the anti-IL-12/23 agents were included. Two ustekinumab studies [51, 52] reported results using the FDA-approved dose and the maximally effective dose of Dermatol Ther (2012) 2:9
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Each individual agent, as well as each class,
showed an increase in the odds of achieving a positive response (Fig. 2) were pooled, regardless of dose, slightly smaller overall effects were seen.
The MTC analysis included data from 13 trials of seven therapies in three drug classes that reported data on the PGA response rate using a static scale and included arms using the FDAapproved dose (Tables 3, 4) [27, 31, 33, 34, 36, 38, 42, 43, 46, 48, [51] [52] [53] . The placebo-based comparisons were similar to those discussed above, although generally had wider credible intervals (CrI). When the drug classes were analyzed, both the anti-TNF agents (OR 6.19, 95% CrI 2.75-12.87) and anti-IL-12/23 agents (OR 7.60, 95% CrI 3.25-18.80) were suggested to be superior to the anti-T cell agents. Pair-wise drug comparisons followed similar trends with many anti-TNF and anti-IL-12/23 agents showing superior results to the anti-T cell agents.
PGA Dynamic Response Rate
Seven RCTs evaluating three drugs from three classes reported data on the PGA response rate using a dynamic scale (Table 2) [28, 29, 31, 33, 35, 39, 50] . All of the RCTs were of high quality (Jadad C4) and ranged from 10 to 12 weeks in duration. All of the studies defined their endpoint using a rating of ''clear'' or ''excellent.'' Efalizumab was the only anti-T cell agent that provided data on the PGA dynamic [35, 39] . Ustekinumab was the only anti-IL-12/23 agent that reported data on this endpoint [50] .
Each individual agent, as well as each class, showed an increase in the odds of achieving a positive response (Fig. 3) [24, 31, 33, 35, 39, 50] . When all anti-T cell agent RCTs (OR 9.73, 95% CI 6.54-14.49) and anti-TNF agent RCTs (OR 140.58, 95% CI 39.14-504.97) were pooled, regardless of dose, similar overall effects were seen.
The MTC analysis included data from six
RCTs of three therapies in three drug classes that reported data on the PGA response rate using a dynamic scale and included arms using the FDA-approved dose [29, 31, 33, 35, 39, 50] .
Due to the small numbers of studies included in the analysis, many indirect comparisons yielded unreliable results (Tables 3, 4) . As a class, the anti-TNF agents were suggested to be superior to the anti-T cell agents (OR 22.53, 95% CrI
2.61-206.3).
Change in DLQI from Baseline
Fifteen RCTs evaluating six drugs from three classes reported data on the change in DLQI score from baseline (Table 2) Five RCTs evaluated the anti-T cell agents, with one alefacept study [26] , and two efalizumab studies [30, 32] reporting results using FDA-approved doses. Seven RCTs evaluated the anti-TNF agents, with three infliximab studies [37, 38, 40] , two adalimumab studies [41] [42] [43] , and one etanercept study [47] reporting results using FDA-approved doses. Ustekinumab was the only anti-IL-12/23 agent that reported data on this endpoint with two studies reporting results using FDA-approved doses [50] [51] [52] .
The anti-T cell agents as a class, as well as efalizumab alone significantly reduced the DLQI score from baseline (Fig. 4) (Table 2) [23, 25, 26, 38, 40, 41, 43, 47] . There were two component scores examined in this category, the physical and mental component summary (PCS and MCS) scores. All of the RCTs were of high quality (Jadad C4) and ranged from 10 to 24 weeks in duration.
Alefacept was the only anti-T cell agent that reported data on these endpoints [23, 25, 26] , with a single RCT [26] reporting results using FDA-approved doses. Five RCTs evaluated the anti-TNF agents, including infliximab [38] [39] [40] , adalimumab [41, 43] , and etanercept [47] , all of which reported results using FDA-approved The MTC analysis included data from seven trials of three therapies in two drug classes that reported data on the change in SF-36 scores (both MCS and PCS) from baseline using the FDAapproved dose (Tables 3, 4) [23, 25, 26, 38, 40, 41, 43] . No differences between individual agents or drug classes were seen in the MTC model.
Statistical Heterogeneity/Publication Bias
Significant statistical heterogeneity was seen with the anti-T cell class for the static PGA Table 4 Mixed treatment comparison meta-analysis results by class Comparison [55, 56] , with more recent data showing only a mild correlation [56] .
Traditional meta-analyses showed that the anti-T cell agents did not have an impact on the SF-36 whereas improvements in both the MCS and PCS were seen with the anti-TNF agents. No significant effects were seen in the MTC model. These results are all intriguing, especially given that the MTC model showed similar point estimates to traditional meta-analysis for the direct placebo comparisons. This suggests that the Bayesian models used were reliable giving higher credence to the indirect comparison results.
The traditional meta-analysis results from this review are similar to those of prior published reports [7, 8, 57, 58] Studies varied by the severity of patients included (as measured by the baseline PASI score), duration of studies (ranging from 8 to 24 weeks), study quality (as assessed using the Jadad score), and inherent differences between the agents themselves. All of the studies included in this review were of high quality (Jadad C4), and the inclusion of only the FDA-approved doses of the drugs into the primary analyses was done in an attempt to provide a somewhat homogeneous sample. Similar to heterogeneity, publication bias could not be assessed in many analyses due to low study numbers. When it was available, publication bias was not likely due to an
Egger's weighted regression statistic P[0.05. The systematic nature of this literature search, in addition to the relatively tight inclusion criteria, likely lead to the lack of publication bias.
Lastly, the short-term nature of many of the studies included in this review precludes extrapolation of our results to patients requiring long-term therapy. Although estimates from the MTC meta-analysis cannot simply be assumed accurate, were considered valid due, in part, to the similar results seen in the placebo-controlled comparisons between the MTC and traditional meta-analytic models.
Various knowledge gaps have been identified by this review. It is clear that comparative effectiveness studies evaluating the impact of biologics continue to be required. When these studies are designed and carried out it should be required that measures of HRQoL are collected and reported. In addition, comparative studies should be of a sufficient duration. As previously stated, most of the studies included in this review were 8-24 weeks in duration. Some included non-randomized 52-week extension studies that provided safety and efficacy data in an observational manner. Studies of a year or more in duration should maintain randomization in order to confirm whether differences seen between groups are seen over the long term.
CONCLUSION
Individual biologics and classes showed consistent benefits across health outcomes in patients with moderate-to-severe plaque psoriasis while MTC meta-analysis suggested that some differences exist. This work provides an important channel in the planning of future clinical trials aimed at defining the most efficacious biologic therapy.
